Cynamon M H, Granato P A
Chemotherapy. 1982;28(3):204-8. doi: 10.1159/000238077.
The in vitro activities of moxalactam, GR 20263, and N-formimidoyl thienamycin were compared to those of cephalothin, cefazolin, cefamandole, cefoxitin, and tobramycin against 152 strains of Enterobacteriaceae and staphylococci. The results showed that moxalactam, GR 20263, and N-formimidoyl thienamycin each had significantly improved activity toward the gram-negative organisms tested compared to the other beta-lactams and tobramycin. N-formimidoyl thienamycin was particularly impressive with respect to its activity toward Staphylococcus aureus and S. epidermidis as compared to moxalactam, GR 20263 and the older beta-lactam drugs.
将羟羧氧酰胺菌素、GR 20263和N-甲脒基硫霉素的体外活性与头孢噻吩、头孢唑林、头孢孟多、头孢西丁和妥布霉素对152株肠杆菌科细菌和葡萄球菌的活性进行了比较。结果表明,与其他β-内酰胺类药物和妥布霉素相比,羟羧氧酰胺菌素、GR 20263和N-甲脒基硫霉素对所测试的革兰氏阴性菌均具有显著增强的活性。与羟羧氧酰胺菌素、GR 20263和较老的β-内酰胺类药物相比,N-甲脒基硫霉素对金黄色葡萄球菌和表皮葡萄球菌的活性尤其令人印象深刻。